Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	697.5	2,005	13,389	560.22	508.7	369.15
Short-Term Investments	50	50	-	0.02	619.01	412.8
Trading Asset Securities	-	-	-	300.05	995.46	503.97
Cash & Short-Term Investments	747.5	2,055	13,389	860.29	2,123	1,286
Cash Growth	-69.18%	-84.65%	1456.29%	-59.48%	65.11%	-9.50%
Accounts Receivable	6,454	4,586	4,220	2,927	1,610	1,405
Other Receivables	-	1,092	1,435	1,617	244.69	282.48
Receivables	6,510	5,736	5,710	4,584	2,084	1,733
Inventory	4,087	3,348	1,890	1,314	1,179	944.66
Prepaid Expenses	-	200.4	256.2	172.83	214.39	79.9
Other Current Assets	2,567	890.6	1,775	715.84	672.23	627.17
Total Current Assets	13,912	12,230	23,020	7,647	6,273	4,670
Property, Plant & Equipment	7,985	7,288	5,583	3,774	1,919	778.78
Long-Term Investments	626.5	622	157.3	68.77	4,208	2,859
Goodwill	9,120	9,120	8,672	3,318	934.74	934.74
Other Intangible Assets	36,288	37,327	29,134	18,806	6,596	6,841
Long-Term Deferred Tax Assets	2,336	2,890	3,070	2,739	2,431	2,006
Other Long-Term Assets	1,322	843.7	758.7	309.96	330.82	208.1
Total Assets	71,600	70,332	70,405	36,673	22,721	18,348
Accounts Payable	3,987	3,324	2,189	1,248	1,178	1,026
Accrued Expenses	-	2,032	972.6	288.05	209.65	184.47
Short-Term Debt	-	3,966	17,488	701.22	92.7	93.14
Current Portion of Long-Term Debt	7,459	2,876	3,319	1,306	-	-
Current Portion of Leases	88.3	120.5	89.8	77.21	40.02	23.2
Current Income Taxes Payable	1,616	436.1	395.9	39	69.97	77.51
Current Unearned Revenue	-	6.3	44.5	37.7	5.65	8.37
Other Current Liabilities	2,079	1,054	821	735.88	400.73	256.46
Total Current Liabilities	15,228	13,814	25,321	4,432	1,996	1,669
Long-Term Debt	15,885	17,375	6,545	6,444	450	-
Long-Term Leases	456.4	442.1	370.2	389.74	353.94	44.47
Long-Term Unearned Revenue	64.3	108.7	76.6	87.39	56.88	61.11
Pension & Post-Retirement Benefits	-	219.2	96.1	38.81	8.92	7.66
Long-Term Deferred Tax Liabilities	4,092	5,185	5,344	2,576	460.94	495.38
Other Long-Term Liabilities	838.5	470.6	431.1	497.39	312.22	305.64
Total Liabilities	36,565	37,614	38,184	14,467	3,639	2,584
Common Stock	136.2	136.2	136	135.99	135.93	135.78
Additional Paid-In Capital	-	293.4	180.7	151.01	106.13	-
Retained Earnings	-	27,928	25,409	21,559	18,737	15,503
Comprehensive Income & Other	30,775	186.4	135.7	113.58	104.52	125.3
Total Common Equity	30,912	28,544	25,862	21,960	19,083	15,764
Minority Interest	4,123	4,174	6,359	246.89	-1.08	0.02
Shareholders' Equity	35,035	32,718	32,221	22,207	19,082	15,764
Total Liabilities & Equity	71,600	70,332	70,405	36,673	22,721	18,348
Total Debt	23,888	24,779	27,813	8,918	936.66	160.81
Net Cash (Debt)	-23,141	-22,725	-14,424	-8,058	1,187	1,125
Net Cash Growth	-	-	-	-	5.46%	-12.85%
Net Cash Per Share	-169.82	-166.73	-105.93	-59.18	8.73	8.28
Filing Date Shares Outstanding	136.27	136.16	136.03	135.99	135.93	135.78
Total Common Shares Outstanding	136.27	136.16	136.03	135.99	135.93	135.78
Working Capital	-1,317	-1,584	-2,300	3,215	4,277	3,001
Book Value Per Share	226.84	209.63	190.12	161.48	140.39	116.10
Tangible Book Value	-14,496	-17,903	-11,943	-164.57	11,552	7,989
Tangible Book Value Per Share	-106.37	-131.48	-87.80	-1.21	84.99	58.84
Land	-	1,175	490.8	229.18	195.33	22.98
Buildings	-	2,464	1,973	1,240	326	326
Machinery	-	4,221	3,525	2,268	1,299	1,207
Construction In Progress	-	667.4	190.6	213.78	240.04	-
Leasehold Improvements	-	116.3	109.9	92.81	84.8	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.